31 results about "Proliferative capacity" patented technology

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

The process provided in this invention transfects primary cells with gene editing reagents using a high-volume gas-permeable cell culture device and a flow-through electroporation device under conditions that improve gene editing performance, cell yield, and drug (DP) quality characteristics for cell therapy applications. As demonstrated in the examples, primary cells edited according to the process provided herein achieved improved double-strand break (DSB) formation rates, increased frequency of homology-directed repair (HR) and non-homologous end joining (NHEJ) combinations, increased frequency of bi-allelic and mono-allelic HR events, improved cell viability, proliferative capacity, and cell fitness after gene editing, and reduced manufacturing time.

The application belongs to the field of biological medicine, and discloses a drug screening method for promoting tumor neoantigen production. The method comprises the following steps: under the condition of immune activation, a to-be-screened compound is applied to a neoantigen generation defect cell model; indexes such as the expression level of the neoantigen or the neoantigen-MHC complex, the immune checkpoint molecule, the survival state or cytotoxicity of tumor cells, the activation or proliferation ability of immune cells, and the like are detected; and the candidate compound is comprehensively evaluated. The method realizes a three-dimensional integrated evaluation system of "neoantigen induction efficiency-tumor cytotoxicity characteristics-T cell immune activity" for the first time, can high-throughput screen a large-scale compound library, specifically recognizes and evaluates the comprehensive effect of the candidate compound, thereby efficiently discovers a lead drug with the activity of promoting tumor neoantigen production, solves the fundamental defect that the existing screening technology cannot target the evaluation of the neoantigen induction capacity, and provides a universal and expandable screening platform for the development of an immunotherapy sensitizer.

This invention provides a chimeric antigen receptor comprising an NFIX-encoding gene, a self-cleaving peptide sequence F2A, and a CAR-encoding sequence. The NFIX-encoding gene is located upstream and is linked to the CAR-encoding sequence via the self-cleaving peptide sequence F2A. The sequence of the NFIX-encoding gene is shown in SEQ ID NO. 01, and the sequence of the self-cleaving peptide sequence F2A is shown in SEQ ID NO. 03. This invention also provides a chimeric antigen receptor T cell expressing the aforementioned chimeric antigen receptor. This invention further provides the application of the aforementioned chimeric antigen receptor or the aforementioned chimeric antigen receptor T cell in the preparation of drugs for treating cancer. This invention improves the antitumor therapeutic effect of CAR-T cells by introducing the NFIX expression element into engineered T cells, thereby enhancing their functional stability, proliferative capacity, and cytotoxic activity under continuous antigen stimulation.

Disclosed are use of a circRNA molecule as a diagnostic marker in a cell senescence diagnosis kit, and use thereof as a treatment target for cell senescence. The present invention finds that circHERC1 is lowly expressed in both cell models of natural senescence and induced senescence. Overexpression of circHERC1 in endothelial cells can improve the proliferation capacity of the endothelial cells, effectively extend the telomere length of the cells, activate telomerase, reduce the β-galactosidase positive rate of the cells, and reduce the expression of all senescence-associated proteins. Introduction of exogenous circHERC1 into mice can effectively delay the senescence of various organs and the shortening of telomeres in aged mice and reduce the β-galactosidase positive rates of various organs of aged mice.

The invention relates to the technical field of immune cell preparation, and particularly discloses an NK cell culture medium, an NK cell and a culture method and application of the NK cell. The NK cell culture medium comprises cell factors IL2, IL21 and TGF beta; the system further comprises IL4. The NK cell obtaining method comprises the step of contacting cells with the culture medium. The NK cells obtained by the invention have relatively high cell proliferation ability, and the proliferation ability, motility and in-vivo effectiveness of the cells after cryopreservation recovery are high.

The application provides a method for enhancing the expansion and activation of memory-like NK cells, and belongs to the technical field of cell culture. The application provides a method for obtaining strong memory-like NK cells, which comprises using complete culture medium, IL-2, IL-12, IL-15, IL-18, sodium alpha-ketoglutarate and DOT1L inhibitor; the concentration of the sodium alpha-ketoglutarate is 0.1-2 mM, and the concentration of the DOT1L inhibitor is 10-100 nM. The addition of low-concentration sodium alpha-ketoglutarate in the complete culture medium of memory-like NK cells can promote the in-vivo and in-vitro proliferation capacity of the memory-like NK cells. The addition of low-concentration DOT1L inhibitor in the late culture stage can further enhance the killing function of the memory-like NK cells by inhibiting H3K79me2 / 3, etc., so that memory-like NK cells with a larger number and stronger killing capacity are obtained.

The application relates to the technical field of biology, and discloses a method for inducing a cell line of immortalized musk deer scent glands to synthesize dihydrotestosterone, wherein the cell line is obtained by transfecting a primary musk deer scent gland epithelial cell with a lentivirus carrying an SV40 Large T antigen and performing resistance screening; the cell line is in an epithelial cell form and stably expresses keratin 18, cholesterol side chain cleavage enzyme, 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase. Through lentivirus-mediated SV40 Large T antigen transfection, the primary musk deer scent gland epithelial cell breaks through the limit of replicative senescence and obtains unlimited proliferation capacity, effectively overcomes the defects that the primary cell is prone to fibrosis and rapidly loses metabolic function during in-vitro culture, provides a standardized cell model with a clear genetic background and persistent metabolic activity for biological manufacturing of dihydrotestosterone, and relieves the dependence on endangered animal live resources.

The application belongs to the technical field of medicine, and discloses application of uridine-5' monophosphate and a compound thereof in preparation of a medicine for enhancing the proliferation ability of male reproductive cells. It is found for the first time that the uridine-5' monophosphate has the proliferation ability on the male reproductive cells, and the proliferation effect is best when the concentration of the uridine-5' monophosphate is 10 μM, the proliferation effect on the mouse TM3 cells is increased by 52.87% compared with a control, and the proliferation effect on the mouse TM4 cells is increased by 53.57%. In addition, the uridine-5' monophosphate has a synergistic ability when being compounded with xylonic acid lactone, and further improves the proliferation effect on the TM3 cells, thereby laying a foundation for treatment of male reproductive system diseases in the future.

This invention relates to the field of biomedical technology, and more particularly to a method for preparing mesenchymal stem cell apoptotic vesicles. The method primarily employs serum-free culture medium for 3D microsphere culture of stem cells, followed by induction of apoptosis into apoptotic vesicles using an apoptosis induction system, resulting in highly efficient apoptotic vesicles. This method significantly enhances the bidirectional immunomodulatory effect of stem cell-derived apoptotic vesicles, greatly expanding the application range and therapeutic efficacy of these vesicles. The serum-free culture medium avoids the safety risks and batch-to-batch variations associated with traditional culture media, and significantly improves the proliferation capacity, passage stability, and immunomodulatory effect of stem cells, enabling stable and efficient acquisition of apoptotic vesicles.

This invention relates to the field of bovine embryonic stem cell culture technology, and particularly to a long-term culture system for morphological bovine embryonic stem cells completely without a feeder layer and its applications. After trying various culture methods, this invention establishes a feeder-free bovine morphological embryonic stem cell line (FF-bESCs). Bovine morphological embryonic stem cells cultured under the feeder-free conditions provided by this invention can maintain stable proliferation capacity and pluripotency over a long period. The bovine morphological embryonic stem cells provided by this invention can undergo gene editing and can be effectively induced to differentiate into primordial germ cell-like cells (PGCLCs). This invention lays an important foundation for the standardized and large-scale culture of bovine embryonic stem cells under feeder-free conditions, and for their application in stem cell breeding and other fields.

Provided are a cell membrane-expressed IL-15 fusion protein and a use thereof in cell therapy. The provided fusion protein comprises an IL-15Rα signal peptide, IL-15, an IL-15Rα sushi domain, and a transmembrane region; and a cell modified with the fusion protein can achieve efficient expression of IL-15 on the surface of a cell membrane, can effectively avoid side effects caused by the secretion and expression of IL-15, and is safe and controllable. An immune cell modified with a chimeric antigen receptor containing the membrane-expressed IL-15 fusion protein has a stronger tumor killing function, higher IFN-γ secretion, and a greater proliferative capacity; after treatment with lactic acid and TGF-β which are abundant in a tumor microenvironment, the immune cell retain a strong tumor killing function; and the immune cell can activate the anti-tumor function of immune cells other than the immune cell. The constructed immune cell can improve the therapeutic effect against tumors, prolong the duration of disease remission, and improve overall survival in patients.

This invention discloses a nucleic acid fragment, nanoliposomes, and their application in the in vivo preparation of CAR-T cells, belonging to the field of immunocellular therapy technology. This invention constructs a CAR nucleic acid fragment that can be delivered in vivo via various methods to obtain in vivo activated and induced enhanced CAR-T cells that secrete IL-4 or IL-10. These CAR-T cells do not secrete IL-4 or IL-10 in a resting state, thus avoiding the inhibitory effects of IL-4 or IL-10 on their proliferative capacity and effector function. When the CAR-T cells are specifically activated by tumor cells, they can secrete IL-4 or IL-10, thereby restoring the vitality of CAR-T cells and enhancing their long-term anti-tumor activity through metabolic reprogramming of IL-4 or IL-10. This invention achieves in vivo induced CAR-T cell generation, with the advantages of simple operation and low cost.

The invention provides herein epigenomic changes identified in old mice compared to young mice or old mice treated with Oct4, Sox2, Klf4 and c-Myc (OSKM). The invention further provides methods of identifying a compound by analyzing one or more PRC2-associated epigenomic change in a sample before and after contacting the sample with one or more compounds. Also provided herein are methods of using compounds identified using the methods described herein for improving proliferative capacity, cell and tissue regeneration, and / or reducing fibrosis.

The present application relates to the technical field of cell culture and cell harvesting, and in particular to a lysis powder and its application in lysis of gelatin-based microcarriers. The present application comprises a lysis enzyme module, an EDTA chelation module and a cell protection module, which can realize rapid lysis of gelatin-based microcarriers and release of cells, improve the proportion of live cells in the harvested cells, and maintain the ability of the harvested cells to adhere, recover and proliferate after being reseeded, thereby being suitable for cell engineering, tissue engineering, cell culture meat and related large-scale production scenarios.

The application provides a healthy human umbilical cord blood-derived immortalized NK cell line SZ093 and a preparation method and application thereof. The healthy human umbilical cord blood-derived immortalized NK cell line SZ093 is preserved in the Guangdong Provincial Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67036. The healthy human umbilical cord blood-derived immortalized NK cell line SZ093 provided by the application can still maintain good proliferation ability and high survival rate in a long-time (more than 1 year) culture process, and has high killing ability to tumor cells.

This invention relates to the field of cell culture technology, and discloses a method for culturing NK cells and its applications. When NK cells enter a hypoxic environment, not only do their cytotoxic activity and proliferative capacity rapidly decline, but they also experience metabolic disorders such as impaired mitochondrial function, insufficient ATP production, and abnormal accumulation of reactive oxygen species (ROS), leading to functional failure and limiting their application in tumor therapy. Existing technologies mainly rely on constant or single-stage hypoxia induction, failing to improve the insufficient hypoxia adaptation of NK cells at the metabolic level. Therefore, this invention provides a method that uses repeated acclimatization culture with gradually decreasing oxygen concentration to allow NK cells to gradually adapt to the metabolic demands of a hypoxic environment. NK cells cultured using this method exhibit a more stable metabolic state and superior cytotoxic activity in a hypoxic environment, significantly enhancing their anti-tumor efficacy and solving the problem of metabolic imbalance and rapid functional loss of NK cells in the hypoxic tumor microenvironment in existing technologies.

The application provides a preparation for enhancing the in-vitro proliferation capacity of pig spermatogonial stem cells, and belongs to the technical field of livestock reproduction. The preparation is composed of a basic culture solution, basic maintenance components, supportive growth factors and a core active component polypeptide Japonicin-1Npb. Research shows that under the condition of approaching the physiological temperature (38.5 DEG C) of pigs, the addition of 25-100 mu g / mL of the polypeptide Japonicin-1Npb can significantly improve the EdU positive rate of pig spermatogonial stem cells, promote cell proliferation, specifically up-regulate the expression of stemness genes PLZF, UCHL1 and GFR alpha 1, and inhibit the differentiation gene c-KIT. The application solves the problems of low in-vitro expansion efficiency and easy loss of stemness of pig spermatogonial stem cells, and the cells still retain good meiotic differentiation potential after the removal of the preparation, thereby providing technical support for the development of high-quality genetic resources of pigs and the research of reproductive biology.

This invention provides a method for creating liver cancer cell lines with clearly defined driver genes based on transposon systems and their applications. Specifically, this invention provides a method based on the SB transposon system, which successfully establishes liver cancer cell lines with stable proliferation capacity by stably introducing oncogenes into wild-type or p53 knockout mouse primary liver cells. These cell lines provide important experimental tools for liver-related research, drug screening, and the study of liver cancer mechanisms.

This invention discloses the application of BHLHE40 in the preparation of prognostic assessment kits and therapeutic drugs for retinoblastoma. Through a series of in vitro and in vivo experiments, this invention demonstrates that knocking down BHLHE40 expression significantly inhibits the proliferation of retinoblastoma cells, exhibiting a significant tumor-suppressive effect. Therefore, it is proposed that BHLHE40 inhibitors can be used in the preparation of therapeutic drugs for retinoblastoma, providing a new, effective, and safe treatment option for RB patients. Furthermore, BHLHE40 can serve as a drug target to guide subsequent drug development. In addition, this invention also utilizes clinical tumor tissue samples to demonstrate that high BHLHE40 expression is significantly positively correlated with high-risk pathological features such as optic nerve invasion, scleral invasion, and choroidal invasion, suggesting that BHLHE40 can serve as an effective biomarker for predicting high-risk pathological features, assisting physicians in treatment decisions.

This invention provides CD33-targeting CAR-gdT cells and their application in the treatment of acute myeloid leukemia. Specifically, this invention, through screening, provides CD33-CAR-γδT cells with high transfection efficiency, strong proliferative capacity, and efficient killing of target cells. This invention also provides a method for preparing CD33-CAR-γδT cells and their application in the treatment of acute myeloid leukemia.

This invention discloses a bioinformatics evaluation and detection method for the bioactivity of stem cell preparations, belonging to the field of stem cell preparation bioactivity evaluation and detection technology. First, basic compliance testing data of the stem cell preparation to be tested is collected. If the basic tests are unqualified, the activity is directly determined to be substandard. For samples that pass the basic tests, transcriptome and proteome data are extracted simultaneously. The two omics data are compared with a pre-constructed multi-source, multi-generational stem cell activity benchmark feature library to calculate a molecular-level activity score. Subsequently, three types of in vitro functional experiments—proliferation capacity, immunosuppressive capacity, and tissue repair capacity—are conducted on the samples to be tested, and a functional-level activity score is calculated. This invention effectively reduces the false positive rate of existing stem cell activity evaluation methods, significantly improves the stability and accuracy of the detection results, and can adapt to the testing needs of various stem cell preparations from different tissue sources and at different passage numbers. The testing process has a high degree of standardization.

This invention discloses an anti-aging compound, its preparation method, and its applications. Experimental results in in vitro anti-aging screening models using MEF cells and MRC-5 cells show that the compound significantly reduces the proportion of cells positive for aging-related β-galactosidase staining, downregulates the protein expression levels of aging markers p53, p21, and p16, and restores the proliferative capacity of senescent cells. In *C. elegans*, the compound prolongs the lifespan of the nematodes, improves their motility, and reduces lipofuscin accumulation due to aging. Therefore, this compound can be used in the preparation of anti-aging drugs and health products. This invention provides new candidate compounds and experimental evidence for the development of new anti-aging drugs and basic research, and has significant practical implications.

This invention belongs to the field of biomedical technology and discloses the application of the KLF13 gene regulator in the aging of large blood vessels' arteries and veins. Through systematic analysis of KLF13 gene knockout mice, this invention demonstrates that KLF13 is an important protective factor in maintaining vascular homeostasis. In vitro experiments show that KLF13 knockdown increases DNA damage and decreases proliferation capacity in cells, suggesting that KLF13 plays a protective role against vascular aging. Among vascular cell types, KLF13 knockdown shows the most significant changes in endothelial cells, resulting in decreased arteriovenous endothelial migration and tubular function. This reveals the core role of KLF13 in maintaining vascular homeostasis. These findings not only establish KLF13's status as a key vascular protective factor at the functional level, but also suggest that its dysfunction may be closely related to the occurrence and development of vascular aging and related diseases. This provides a theoretical and practical basis for developing products that identify vascular cell aging.

This development represents a method for conditioning cells grown under in vitro conditions in the presence of biochemical and / or metabolic stimuli, specifically cellular reprogramming factors, emergency stimuli, and metabolic activity stimulants. This method is intended for the reversal of the aging of treated cells, restoring their regenerative and proliferative capacities, and generating conditioned media with properties that restore cell youthfulness and proliferation.

This invention discloses an anti-aging compound, its preparation method, and its applications. Experimental results in in vitro anti-aging screening models using MEF cells and MRC-5 cells show that the compound significantly reduces the proportion of cells positive for aging-related β-galactosidase staining, downregulates the protein expression levels of aging markers p53, p21, and p16, and restores the proliferative capacity of senescent cells. In *C. elegans*, the compound prolongs the lifespan of the nematodes, improves their motility, and reduces lipofuscin accumulation due to aging. Therefore, this compound can be used in the preparation of anti-aging drugs and health products. This invention provides new candidate compounds and experimental evidence for the development of new anti-aging drugs and basic research, and has significant practical implications.

This invention discloses a method for rejuvenating senescent cells based on osmotic pressure induction. Senescent cells typically exhibit cell volume expansion. This method constructs a hypertonic environment by introducing a biocompatible polymeric solute (such as 2% or 0.5% PEG 300), applying controlled hypertonic pressure to senescent cells to induce cytoplasmic dehydration and counteract volume expansion. Experiments have demonstrated that long-term hypertonic compression intervention (such as 7 days of 0.5% PEG treatment) can effectively reset the mechanical state of senescent cells. After removing the pressure and restoring isotonic culture, some senescent cells can regain their proliferative capacity, as evidenced by negative SA-β-gal staining, strong positivity for Ki67 and EdU proliferation markers, and long-term stable passage. This invention provides a non-genetic, physical means to achieve cell rejuvenation, offering a new pathway for the intervention of age-related diseases.